Published in Hepatitis Weekly, May 8th, 1995
Researchers at New York's Roswell Park Cancer Institute and Texas A&M University report that hepatitis B surface antigen (HBsAg) produced by genetically engineered tobacco plants are nearly as immunogenic as the expensive yeast-derived antigens now used in commercially available hepatitis B vaccines.
"The focus of the Children's Vaccine Initiative is to encourage the discovery of technology that will make vaccines more readily available to developing countries," Y. Thanavala and colleagues wrote in the April 11, 1995,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.